Immunodiagnostic trims jobs as sales slump in the past year

Immunodiagnostic Systems' fully automated system for lab and clinic tests
Immunodiagnostic Systems' fully automated IDS-iSYS Multi- Discipline Automated System

British laboratory and clinic testing kit maker Immunodiagnostic Systems says slumping sales have cost 31 jobs at its Boldon manufacturing facility over the past 12 months.

In its full-year trading update, the company said full-year sales for the 12 months ended March 31 fell 13% to about £39 million ($57 million). The company, which makes both manual and automated testing kits, said the losses were mostly due to sluggish sales in its manual assay business where test volumes continue to move toward automated solutions where there is more competition, the Chronicle reported.

Immunodiagnostic reported a total of 315 employees on a full time basis, which is down 31 from a year ago.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The company has manufacturing facilities in Boldon and Italy, as well as an instrument production and system engineering in France and a manufacturing facility in Liege, Belgium.

The declines in sales are expected to last through this year.

- check out the Chronicle story

Related Articles:
Embark Veterinary launches DNA testing kit for dogs
European investor shells out $118M for DNA testing outfit to boost animal Dx offerings

Image courtesy of Immunodiagnostic Systems


Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.